New insider activity at Fulgent Genetics ( (FLGT) ) has taken place on March 6, 2025.
CFO & Treasurer Paul Kim has made a significant investment in Fulgent Genetics by purchasing 100,000 shares of the company’s stock, with the transaction valued at $1,596,000.
Recent Updates on FLGT stock
Fulgent Genetics experienced a 2.5% increase in its stock price following the announcement that CFO Paul Kim purchased 100,000 shares of common stock. However, analysts at Piper Sandler and UBS lowered their price targets for the company due to recent financial results and future growth expectations. Piper Sandler adjusted their target following Fulgent’s quarterly results, while UBS cited a slight Q4 earnings beat but expressed concerns over decelerating growth in the company’s oncology and pathology business. Despite reporting a GAAP loss for 2024, Fulgent showcased strong revenue growth and advancements in clinical trials, projecting a 10% year-over-year growth in core revenue for 2025. The company remains optimistic about its future prospects, driven by strategic partnerships and a robust clinical pipeline, although it anticipates lower operating margins due to ongoing investments.
More about Fulgent Genetics
YTD Price Performance: -15.74%
Average Trading Volume: 265,791
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $478.5M